Oncology Building a Phase I oncology centre The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.
R&D Universities and pharma companies need each other to create ... Academics and pharma executives seemingly live in very different worlds.
News ADARx, Trex, and Retension take aim at IPOs The appetite among biotechs for IPOs shows no signs of being satisfied, with three more – ADARx, TRex, and Retension – making their intentions known.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
